Plexxikon teams up with Roche, eyes $335M to fight kidney disease
Pharmaceutical company Plexxikon has joined forces with health care giant Roche for at least $60 million to develop a treatment for polycystic kidney disease, commonly called PKD. Under the terms of the deal, Roche will have full global rights to commercialize and market the compound,… Continue Reading